Respiratory Virus Sampling and Repository

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Mar 3, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on studying respiratory viruses like influenza and COVID-19. Researchers want to collect samples from individuals who are infected or suspected to be infected with these viruses to better understand how these infections affect people and how the immune system responds to them. The findings from this study could help improve future treatments and preventive measures for respiratory viruses.

To participate, you need to be at least 3 years old and either have a confirmed or suspected respiratory virus infection. If you join the study, you will provide blood and nose samples, and possibly saliva samples, which can be done at home using kits sent to you. The study will last up to 2 years, during which your health information will also be collected. Importantly, non-English speakers can participate, as the study will be explained through interpreters to ensure everyone understands the process.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• • 1. Aged 3 years or older.
• • 2. Documented or suspected infection with a respiratory virus.
• • 3. Stated willingness to comply with all study procedures for the duration of the study.
• EXCLUSION CRITERIA:
• An individual who meets any of the following criteria will be excluded from participation in this study:
• • 1. Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study.
• • Non-English Speaking Participants: This study will enroll non-English speaking participants.
• • For non-English speaking participants, the study will be explained to the participant/family through an interpreter, in the presence of the study team, in the language understood by the participant/family. The short form in the language understood by the participant/family will be signed by the participant/family or LAR and the interpreter, and the consent will be signed by the consenting provider and the interpreter.